沙格列汀对2型糖尿病患者HOMA-2指数及血脂影响的Meta分析  

Effect of Saxagliptin on the HOMA-2 Model and Blood Lipids of Patients with Type 2 Diabetes: a Meta-analysis

作　　者：文恩辉 李莹 魏世杰[3] 高华[3] 党宏万[3] Wen Enhui;Li Ying;Wei Shijie;Gao Hua;Dang Hongwan(Clinical Pharmaceutics Room,the First Affiliated Hospital of Xi'an Medical University,Xi'an 710077,China;Department of Traditional Chinese Medicine,Xi'an Mental Health Center;Department of Pharmacy,General Hospital of Ningxia Medical University)

机构地区：[1]西安医学院第一附属医院临床药学室,西安710077 [2]西安市精神卫生中心中医科 [3]宁夏医科大学总医院药剂科

出　　处：《药物流行病学杂志》2019年第11期711-716,共6页Chinese Journal of Pharmacoepidemiology

摘　　要：目的:评价沙格列汀对2型糖尿病患者稳态模型2(HOMA-2)指数及血脂的影响。方法:计算机检索CNKI、WanFang Data、SinoMed、VIP、PubMed、Embase、The Cochrane Library、Web of Science数据库,搜集沙格列汀对2型糖尿病患者HOMA-2指数和血脂影响的随机对照试验(RCT),检索时限均从建库至2019年9月。由两名研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用RevMan 5.3软件进行Meta分析。结果:共纳入13个RCTs,合计3422例患者。Meta分析结果显示,沙格列汀较安慰剂可提高2型糖尿病患者HOMA-2β指数[MD=6.31,95%CI(1.70,10.92),P<0.001];沙格列汀联合其他口服降糖药较其他口服降糖药单药治疗可提高2型糖尿病患者HOMA-2β指数(P<0.05),并降低患者HOMA-2IR指数[MD=-0.18,95%CI(-0.30,-0.06),P<0.001],但对于血脂水平的影响,差异无统计学意义(P>0.05)。结论:沙格列汀可以改善患者胰岛素β分泌功能,但其对血脂的调节不优于传统口服降糖药,由于纳入研究数目较少,上述结论尚待更多高质量研究予以验证。Objective:To assess the effect of saxagliptin on HOMA-2 and blood lipids in people with type 2 diabetes mellitus.Methods:CNKI,WanFang Data,SinoMed,VIP,PubMed,Embase,The Cochrane Library and Web of Science diabetes were electronically searched to collect randomized controlled trial(RCT)that saxagliptin affect the HOMA-2 model and blood lipids of patients with type 2 diabetes from inception to September 2019.Two researchers independently screened literature,extracted data and assessed the risk of bias of included studies,then,Meta-analysis was performed by using RevMan 5.3 software.Results:Thirteen RCTs,involving 3422 participants were included.The results of Meta-analysis showed,saxagliptin in comparison with placebo group resulted in HOMA-2βincrease(MD=6.31,95%CI 1.70 to 10.92,P<0.001).Compared with other oral hypoglycemic agents,saxagliptin combined with other oral hypoglycemic agents could improved HOMA-2β(P<0.05),and lowered HOMA-2 IR level(MD=-0.18,95%CI-0.30 to-0.06,P<0.001).However,the difference in blood lipid levels between two groups was not statistically significant(P>0.05).Conclusion:Saxagliptin could improveβcell function and had no positive effects on blood lipids in type 2 diabetes patients.However,due to the limited quantity of the included studies,further larger studies are needed to support this finding.

关 键 词：沙格列汀 META分析 2型糖尿病 稳态模型2指数 血脂 

分 类 号：R977.15[医药卫生—药品]